Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival-Reference-Cited by-同舟云学术

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival

Published:2014-05-28 Issue:1 Volume:136 Page:127-137
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

De Remigis Alessandra¹,de Gruijl Tanja D.²,Uram Jennifer N.³,Tzou Schey-Cherng¹,Iwama Shintaro¹,Talor Monica V.¹,Armstrong Todd D.³,Santegoets Saskia J.A.M.²,Slovin Susan F.⁴⁵,Zheng Lei³,Laheru Daniel A.³,Jaffee Elizabeth M.³,Gerritsen Winald R.²,van den Eertwegh Alfons J.M.²,Le Dung T.³,Caturegli Patrizio¹⁶

Affiliation:

1. Department of Pathology; Johns Hopkins University; Baltimore MD

2. Department of Medical Oncology; VU University Medical Centre; Amsterdam The Netherlands

3. The Sidney Kimmel Cancer Center; The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins; Baltimore MD

4. Department of Medicine; Memorial Sloan-Kettering Cancer Center; New York NY

5. Department of Medicine; Weill-Cornell Medical College; New York NY

6. Feinstone Department of Molecular Microbiology and Immunology; Johns Hopkins Bloomberg School of Public Health; Baltimore MD

Funder

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference42 articles.

1. Immunotherapy for prostate cancer: biology and therapeutic approaches;Cha;J Clin Oncol,2011

2. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity;Dranoff;Proc Natl Acad Sci USA,1993